These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12679199)

  • 21. Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.
    Hersberger M; von Eckardstein A
    Drugs; 2003; 63(18):1907-45. PubMed ID: 12930163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of HDL in the prevention of cardiovascular events].
    Paragh G; Harangi M
    Orv Hetil; 2001 Jan; 142(3):121-6. PubMed ID: 11217160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
    Sacks FM
    Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low high-density lipoprotein cholesterol: current status and future strategies for management.
    Singh V; Sharma R; Kumar A; Deedwania P
    Vasc Health Risk Manag; 2010 Oct; 6():979-96. PubMed ID: 21127701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
    Sprecher DL
    Am J Cardiol; 2000 Dec; 86(12A):46L-50L. PubMed ID: 11374856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
    Rizos E; Mikhailidis DP
    Cardiovasc Res; 2001 Nov; 52(2):199-207. PubMed ID: 11684067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HDL therapy for cardiovascular diseases: the road to HDL mimetics.
    White CR; Datta G; Zhang Z; Gupta H; Garber DW; Mishra VK; Palgunachari MN; Handattu SP; Chaddha M; Anantharamaiah GM
    Curr Atheroscler Rep; 2008 Oct; 10(5):405-12. PubMed ID: 18706282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
    Flores-Castillo C; Zamora-Pérez JÁ; Carreón-Torres E; Arzola-Paniagua A; Aguilar-Salinas C; López-Olmos V; Fragoso JM; Luna-Luna M; Rodríguez-Pérez JM; Franco M; Vargas-Alarcón G; Pérez-Méndez Ó
    Fundam Clin Pharmacol; 2015 Aug; 29(4):362-70. PubMed ID: 25982284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statins and metabolism of high density lipoprotein.
    Sviridov D; Nestel P; Watts G
    Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):215-21. PubMed ID: 17630948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-density lipoprotein cholesterol and the role of statins.
    Chong PH; Kezele R; Franklin C
    Circ J; 2002 Nov; 66(11):1037-44. PubMed ID: 12419937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The triglyceride-high-density lipoprotein axis: an important target of therapy?
    Szapary PO; Rader DJ
    Am Heart J; 2004 Aug; 148(2):211-21. PubMed ID: 15308990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
    Boden WE; Pearson TA
    Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
    Katabami T; Murakami M; Kobayashi S; Matsui T; Ujihara M; Takagi S; Higa M; Ichijo T; Ohta A; Tanaka Y
    J Int Med Res; 2014 Apr; 42(2):457-67. PubMed ID: 24595147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Nicotinic acid increases cellular transport of high density lipoprotein cholesterol in patients with hypoalphalipoproteinemia].
    Figueroa C; Droppelmann K; Quiñones V; Amigo L; Mendoza C; Serrano V; Véjar M; Maiz A; Rigotti A
    Rev Med Chil; 2015 Sep; 143(9):1097-104. PubMed ID: 26530191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.
    Messas N; Dubé MP; Tardif JC
    Curr Atheroscler Rep; 2017 Sep; 19(11):43. PubMed ID: 28944433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
    Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.